SI2121898T1 - Postopek za ohranitev virusnih delcev - Google Patents

Postopek za ohranitev virusnih delcev

Info

Publication number
SI2121898T1
SI2121898T1 SI200830486T SI200830486T SI2121898T1 SI 2121898 T1 SI2121898 T1 SI 2121898T1 SI 200830486 T SI200830486 T SI 200830486T SI 200830486 T SI200830486 T SI 200830486T SI 2121898 T1 SI2121898 T1 SI 2121898T1
Authority
SI
Slovenia
Prior art keywords
viral particles
polyethyleneimine
preserving
concentration
preserving viral
Prior art date
Application number
SI200830486T
Other languages
English (en)
Slovenian (sl)
Inventor
Jeffrey Drew
Original Assignee
Stabilitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stabilitech Ltd filed Critical Stabilitech Ltd
Publication of SI2121898T1 publication Critical patent/SI2121898T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Jellies, Jams, And Syrups (AREA)
SI200830486T 2007-03-19 2008-03-19 Postopek za ohranitev virusnih delcev SI2121898T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0705245.9A GB0705245D0 (en) 2007-03-19 2007-03-19 Stable biological products
US91722007P 2007-05-10 2007-05-10
EP08718824A EP2121898B8 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
PCT/GB2008/000987 WO2008114021A1 (en) 2007-03-19 2008-03-19 Method for preserving viral particles

Publications (1)

Publication Number Publication Date
SI2121898T1 true SI2121898T1 (sl) 2012-02-29

Family

ID=38008686

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830486T SI2121898T1 (sl) 2007-03-19 2008-03-19 Postopek za ohranitev virusnih delcev

Country Status (18)

Country Link
US (1) US8313897B2 (cg-RX-API-DMAC7.html)
EP (1) EP2121898B8 (cg-RX-API-DMAC7.html)
JP (1) JP2010521961A (cg-RX-API-DMAC7.html)
KR (1) KR20100015613A (cg-RX-API-DMAC7.html)
CN (1) CN101636486A (cg-RX-API-DMAC7.html)
AT (1) ATE525455T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008228086A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808960A2 (cg-RX-API-DMAC7.html)
CA (1) CA2681182A1 (cg-RX-API-DMAC7.html)
DK (1) DK2121898T3 (cg-RX-API-DMAC7.html)
ES (1) ES2370675T3 (cg-RX-API-DMAC7.html)
GB (2) GB0705245D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20110814T1 (cg-RX-API-DMAC7.html)
IL (1) IL200671A0 (cg-RX-API-DMAC7.html)
PL (1) PL2121898T3 (cg-RX-API-DMAC7.html)
RU (1) RU2009138344A (cg-RX-API-DMAC7.html)
SI (1) SI2121898T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008114021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
KR20110079670A (ko) * 2008-09-24 2011-07-07 스타빌리테크 리미티드 슈가 및 폴리에틸렌이민을 사용하여 폴리펩티드를 보존하는 방법
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
EP2435554B1 (en) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
CA2785815C (en) * 2010-01-28 2018-04-24 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
ES2543795T3 (es) 2010-03-31 2015-08-21 Stabilitech Ltd. Estabilización de partículas virales
WO2011121305A2 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
DK2552478T3 (en) * 2010-03-31 2017-03-27 Stabilitech Ltd EXCIPIENTS FOR STABILIZING VIRUS PARTICLES
NZ607226A (en) 2010-08-13 2015-03-27 Advanced Bionutrition Corp Dry storage stabilizing composition for biological materials
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN108347982A (zh) 2015-07-29 2018-07-31 高级生物营养公司 用于特殊饮食用途的稳定的干燥益生菌组合物
WO2017035664A1 (en) 2015-09-02 2017-03-09 Mcmaster University Enhanced thermal stability for adenoviral vectors through spray drying
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US11626228B2 (en) * 2016-12-22 2023-04-11 Rogers Corporation Multi-layer magneto-dielectric material
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
US12377142B2 (en) 2018-03-07 2025-08-05 Transgene Recombinant pseudocowpoxvirus
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US20210345602A1 (en) * 2018-09-28 2021-11-11 Otsuka Pharmaceutical Factory, Inc Mammal cell preserving solution containing acarbose or stachyose
US12263197B2 (en) 2018-10-30 2025-04-01 The University Of Tokyo Oncolytic virus for cancer therapy
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
EP3996732A4 (en) * 2020-04-14 2022-08-24 Spectrum Solutions, LLC ASSAYS AND METHODS FOR DETECTION OF VIRAL NUCLEIC ACIDS
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
KR20230152035A (ko) 2021-02-01 2023-11-02 에쓰티 피에이치아이 테라퓨틱스 컴퍼니 리미티드 표적 단백질 분해 시스템 및 이의 응용
WO2022246323A1 (en) * 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN113655057A (zh) * 2021-08-24 2021-11-16 威世药业（如皋）有限公司 一种检测冷冻干燥处理对痘苗病毒毒力影响的设备
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5459698A (en) * 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
CA2400318C (en) 2000-02-08 2005-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20040110267A1 (en) * 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
RS20080138A (sr) * 2005-10-07 2009-07-15 Pfizer Products Inc., Vakcine i metode lečenja influence kod canina

Also Published As

Publication number Publication date
PL2121898T3 (pl) 2012-02-29
RU2009138344A (ru) 2011-04-27
ATE525455T1 (de) 2011-10-15
GB0915291D0 (en) 2009-10-07
IL200671A0 (en) 2011-08-01
GB2459611A (en) 2009-11-04
US20100015177A1 (en) 2010-01-21
CN101636486A (zh) 2010-01-27
US8313897B2 (en) 2012-11-20
WO2008114021A1 (en) 2008-09-25
GB0705245D0 (en) 2007-04-25
JP2010521961A (ja) 2010-07-01
HRP20110814T1 (hr) 2012-01-31
GB2459611B (en) 2011-02-16
KR20100015613A (ko) 2010-02-12
CA2681182A1 (en) 2008-09-25
AU2008228086A1 (en) 2008-09-25
DK2121898T3 (da) 2012-01-09
EP2121898B1 (en) 2011-09-21
BRPI0808960A2 (pt) 2014-08-26
EP2121898B8 (en) 2012-02-15
EP2121898A1 (en) 2009-11-25
ES2370675T3 (es) 2011-12-21

Similar Documents

Publication Publication Date Title
GB2459611B (en) Method for preserving viral particles
GB2479069A (en) Method for preserving polypeptides using a sugar and polyethyleneimine
WO2006070370A3 (en) Stem cells culture systems
WO2009007852A3 (en) Multipotent/pluripotent cells and methods
WO2009118253A3 (en) Hair styling composition
WO2010028112A3 (en) Quantum dots, methods of making quantum dots, and methods of using quantum dots
NO20065355L (no) Materialer som inneholoder en hul glucanpartikkel eller en celleveggkomponent som innkapsler en terpenkomponen, samt fremgangsmater for anvendelse av samme
WO2008019871A3 (de) Neue salze des wirkstoffs rasagilin
TW200700092A (en) Tigecycline compositions and methods of preparation
WO2011091420A3 (en) Osteogenic cell delivery matrix
WO2006116622A3 (en) Novel methods and devices for evaluating poisons
NO20080158L (no) Oyedraper som inneholder roflumilast
MX2014007643A (es) Edulcorante natural y metodo para elaborarlo.
WO2010020910A3 (en) Method for generating a cipher-based message authentication code
BRPI0923357A2 (pt) Métodos para acelerar o crescimento de raízes em uma planta, e para melhorar a absorção foliar de um composto biologicamente ativo por uma planta.
WO2011115809A3 (en) High energy radiation insensitive analyte sensors
WO2010059433A3 (en) Mems pressure and acceleration dosimeter
UA100394C2 (en) Lipoic acid pellet composition
WO2007050462A3 (en) Method of treating silica and inkjet recording material
Ni et al. The self-force and effective mass of a generally accelerating dislocation I: Screw dislocation
WO2007046890A8 (en) Lozenge for treatment of dry mouth and related conditions
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
WO2011097664A3 (de) Testanordnung
HK1159119B (en) Method for preserving polypeptides using a sugar and polyethyleneimine
WO2011062559A8 (en) Methods of enhancing pluripotentcy